LG AI Research, a part of the South Korean LG Group, has announced the launch of its new AI-based model, EXAONE Path 2.0, for pathology research.

According to a report by Yonhap, this new version offers significantly improved accuracy in analyzing genetic mutations, gene expression patterns, and minor structural changes in human cells, utilizing pathological images.

The model has been trained on over 10,000 datasets, encompassing visualization and multi-omics, allowing it to predict gene activity solely based on image analysis, negating the need for expensive genomic testing.

«With EXAONE Path 2.0, genetic testing can be completed in less than a minute, compared to the more than two weeks it used to take. This will save precious time for treating cancer patients,» said LG AI Research's lead researcher, Pak Yong-min.

He added that doctors and pharmaceutical companies can utilize EXAONE Path 2.0 for rapid analysis of pathological images in cancer patients, identifying gene mutations and selecting appropriate targeted therapies.

As previously reported, the Chinese company DeepSeek has also introduced its updated AI-based model DeepSeek R1, increasing competition with OpenAI, the developer of the popular chatbot ChatGPT.